StockrabitBrowse analysts
Analyst questions

Rishabh Tripathi

Firm not listed in source transcripts
SUPRIYA

Supriya Lifescience Limited

All company calls
Supriya Lifescience Limited
14 Aug 2026
Open call
  1. So, my first question is on the line of since we are talking about CMO, CDMO. So, a lot of R&D effort would be going on in this direction. But at the same time, molecules come and go. Every project would not be successful, but there would be a lot of learning coming out of it.

    Read in transcript
  2. My second question would be around, with all these learnings and the efforts that are going into R&D, how we are trying to build a system. Let's say, right now, we talk a lot about launching products, one product after another. But from going through the block of, let's say, growth of 2-3 years, how we are trying to build a system which thinks in terms of block of 5 years, 7 years, 10 years.

    Read in transcript
  3. Just one point like as last participant also mentioned that since we are moving into direction with interaction with maybe our partners would be of much larger size, innovators and the other stuff is compliance piece becomes pretty critical. Any lapse there would cost us a bit. So, hopefully this is one of the incidents which happened , and it will not be a recurring thing. Thanks for all the answers.

    Read in transcript